Natler
@Hai: geiler Artikel... kannte ich noch nicht...zwar von 2016 aber hochaktuell... Last week, Sarepta struck a research deal with Catabasis to combine its exon-skipping drugs with experimental treatments from Catabasis that block a protein, NF-kB, implicated in inflammation and muscle degeneration in Duchenne patients.